Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells

The prognosis for patients with disseminated lung cancer is poor and current treatments have limited survival benefit as resistance often occurs, and is often associated with significant toxicity. A possible strategy to improve treatment and evade chemoresistance may be to find new combinations of d...

Full description

Saved in:
Bibliographic Details
Published in:BMC research notes 2017-11, Vol.10 (1), p.544-544, Article 544
Main Authors: Sooman, Linda, Gullbo, Joachim, Bergqvist, Michael, Bergström, Stefan, Lennartsson, Johan, Ekman, Simon
Format: Article
Language:English
Subjects:
Analysis
Bortezomib
Cancer therapies
Chemoresistance
Chemotherapy
Cisplatin
Combination chemotherapy
Combination drug therapy
Complications and side effects
Cytotoxicity
Diagnosis
Dosage and administration
Drug therapy
Epidermal growth factor
Gefitinib
Gemcitabine
Kinases
Lung cancer
Lymphoma
Medical prognosis
Medicin och hälsovetenskap
Multiple myeloma
Mutation
Patients
Prognosis
Proteasome inhibitors
Proteins
Tumor cell lines
Vinorelbine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis for patients with disseminated lung cancer is poor and current treatments have limited survival benefit as resistance often occurs, and is often associated with significant toxicity. A possible strategy to improve treatment and evade chemoresistance may be to find new combinations of drugs. The aim of this study was to analyze the potential of combining proteasome inhibitors (PIs) with chemotherapeutic drugs used in the routine treatment for lung cancer patients. The median-effect method was applied to the Fluorometric Microculture Cytotoxicity Assay (FMCA) to evaluate effects of combining two different PIs (bortezomib and b-AP15) with clinically used chemotherapeutic drugs representing different mechanisms of action (cisplatin, gefitinib, gemcitabine and vinorelbine) in two lung cancer cell lines (one sensitive and one resistant). Proteasome inhibition in combination with cisplatin, gemcitabine or vinorelbine had synergistic effects in at least one of the tested cell lines. Furthermore, the effect of gefitinib appeared strongly potentiated by the PI in the least resistant lung cancer cell line, although the level of synergy could not be determined with the median-effect method. Combining PIs with cisplatin, gefitinib, gemcitabine or vinorelbine show potential as new combination chemotherapy for the treatment of lung cancer.
ISSN:1756-0500
1756-0500
DOI:10.1186/s13104-017-2842-z